Marc Voigt's guest appearances

Marc Voigt

CommSec Market Update

The Bellcast

LifeSci Partners Presents: Benchtop Bios

Chris Bennett

Peter Gray

Andrew Campion

James Holt

David Schwartz

Paul Thompson

Martin Barrett

Hamish Douglass

Andrew Weaver

Helen Chong

Alex Pollak

Rob Nash

Janus Henderson

Phil McKenzie

Simon Owen

OwlTail

Along with the first-ever approval by the FDA of a so-called checkpoint inhibitor, the anti-CTLA-4 drug Yervoy, in 2001, came vindication; the treatment modality of immuno-oncology (IO) had arrived. Anti-PD-1 drugs soon followed with even greater—far greater impact. But then came some failures, and the presumed bright future of other IO assets began to dim. Until now. The first LAG-3-targeting drug was recently approved, and as of ASCO 2022, Immutep’s LAG-3 asset is poised to replace IO/chemo in the front-line setting for NSCLC. Hear CEO Marc Voigt parse the data, and describe the development program going forward.

Along with the first-ever approval by the FDA of a so-called checkpoint inhibitor, the anti-CTLA-4 drug Yervoy, in 2001, came vindication; the treatment modality of immuno-oncology (IO) had arrived. Anti-PD-1 drugs soon followed with even greater—far greater impact. But then came some failures, and the presumed bright future of other IO assets began to dim. Until now. The first LAG-3-targeting drug was recently approved, and as of ASCO 2022, Immutep’s LAG-3 asset is poised to replace IO/chemo in the front-line setting for NSCLC. Hear CEO Marc Voigt parse the data, and describe the development program going forward.

Phase II POC for Immutep’s LAG-3 drug, eftilagimod alpha: ASCO data, and an introduction to CEO Marc Voigt 

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.In this video Marc discusses:(0:40) What IMM does and its key strength in the market(1:27) The impact of the FDA's recent feedback on its lead product(2:53) IMM's collaborations with big pharma names like Pfizer &amp; Merck(4:03) When to expect data from its current clinical trials(5:10)  What's coming up for IMM  Note: This interview was filmed on 22 March 2022. 

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.In this video Marc discusses:<ul><li>(0:40) What IMM does and its key strength in the market</li><li>(1:27) The impact of the FDA's recent feedback on its lead product</li><li>(2:53) IMM's collaborations with big pharma names like Pfizer &amp; Merck</li><li>(4:03) When to expect data from its current clinical trials</li><li>(5:10)  What's coming up for IMM </li></ul> Note: This interview was filmed on 22 March 2022.

From the helm: Immutep's (ASX:IMM) Executive Director & CEO Marc Voigt

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients' tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results... In this video Marc discusses:- (0:40) IMM's progress: the year that was, and the year ahead- (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck- (2:29) Its unique discovery in immunotherapy - which spells new opportunities- (4:02) Key catalysts that could drive share price growth- (6:00) Fund managers who bought into IMM recently - and how funds raised will be spentThis interview was filmed on 18 August 2021. 

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt. Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients' tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results... In this video Marc discusses: - (0:40) IMM's progress: the year that was, and the year ahead - (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck - (2:29) Its unique discovery in immunotherapy - which spells new opportunities - (4:02) Key catalysts that could drive share price growth - (6:00) Fund managers who bought into IMM recently - and how funds raised will be spent This interview was filmed on 18 August 2021.